No material news briefings were provided in context for this reporting period. The report is therefore based on verified SEC filing data, insider transaction records, and institutional holdings disclosures as detailed below.
Pfizer's trailing twelve-month revenue stood at $63.70 billion as of the quarter ended 2026-06-28, representing year-over-year growth of 2.60% [SEC 10-Q - PFE - 2026-06-28]. Net income for the same period was $4.33 billion, producing a net margin of 6.80% and an operating margin of 35.19%. Earnings per share declined 107.84% year-over-year, reflecting significant pressure on the bottom line relative to the prior comparable period. The company carried $976 million in cash against total debt of $63.19 billion. The price-to-earnings ratio was recorded at 36.38 [SEC 10-Q - PFE - 2026-06-28].
Insider activity over the past 30 days recorded one transaction, directionally classified as buying, with a net transaction value of approximately $1.00 million [SEC Form 4 - PFE - 2026-09]. On the institutional side, multiple significant position changes were disclosed. Citadel added 15% to its existing PFE position, AQR Capital added 56%, and Millennium added 28% to their respective holdings. Bridgewater opened a new position in PFE during the same reporting period [SEC 13F - Citadel - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Millennium - Q2 2026] [SEC 13F - Bridgewater - Q2 2026]. These simultaneous additions across multiple large institutional filers constitute the material ownership changes that triggered this report.
The prevailing macro environment features a 10-year US Treasury yield of 4.83% and a 2-year yield of 4.39%, producing a normal yield curve spread of approximately 44 basis points [FRED DGS10] [FRED DGS2]. This rate environment influences the cost of capital calculations relevant to companies carrying significant long-term debt loads, such as the $63.19 billion in total debt recorded on Pfizer's balance sheet as of the most recent filing period [SEC 10-Q - PFE - 2026-06-28].